Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans

Hae Yoon Choi, Sungeun Kim, Ji Woo Park, Nam Seok Lee, Soon Young Hwang, Joo Young Huh, Ho Cheol Hong, Hye-Jin Yoo, Sei-Hyun Baik, Byung Soo Youn, Christos S. Mantzoros, Kyung Mook Choi

Research output: Contribution to journalArticle

36 Citations (Scopus)

Abstract

Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.

Original languageEnglish
Pages (from-to)2778-2785
Number of pages8
JournalJournal of Clinical Endocrinology and Metabolism
Volume99
Issue number8
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Sarcopenia
Brown Adipose Tissue
Muscle
Skeletal Muscle
Tissue
Positron emission tomography
Fluorodeoxyglucose F18
Positron-Emission Tomography
Fats
White Adipose Tissue
Intra-Abdominal Fat
Serum
Research Design
Obesity
Enzyme-Linked Immunosorbent Assay
X-Rays
X rays

ASJC Scopus subject areas

  • Biochemistry
  • Clinical Biochemistry
  • Endocrinology
  • Biochemistry, medical
  • Endocrinology, Diabetes and Metabolism

Cite this

Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. / Choi, Hae Yoon; Kim, Sungeun; Park, Ji Woo; Lee, Nam Seok; Hwang, Soon Young; Huh, Joo Young; Hong, Ho Cheol; Yoo, Hye-Jin; Baik, Sei-Hyun; Youn, Byung Soo; Mantzoros, Christos S.; Choi, Kyung Mook.

In: Journal of Clinical Endocrinology and Metabolism, Vol. 99, No. 8, 01.01.2014, p. 2778-2785.

Research output: Contribution to journalArticle

Choi, Hae Yoon ; Kim, Sungeun ; Park, Ji Woo ; Lee, Nam Seok ; Hwang, Soon Young ; Huh, Joo Young ; Hong, Ho Cheol ; Yoo, Hye-Jin ; Baik, Sei-Hyun ; Youn, Byung Soo ; Mantzoros, Christos S. ; Choi, Kyung Mook. / Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans. In: Journal of Clinical Endocrinology and Metabolism. 2014 ; Vol. 99, No. 8. pp. 2778-2785.
@article{d47ef66b08224289a3e4433451877a86,
title = "Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans",
abstract = "Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1{\%}) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.",
author = "Choi, {Hae Yoon} and Sungeun Kim and Park, {Ji Woo} and Lee, {Nam Seok} and Hwang, {Soon Young} and Huh, {Joo Young} and Hong, {Ho Cheol} and Hye-Jin Yoo and Sei-Hyun Baik and Youn, {Byung Soo} and Mantzoros, {Christos S.} and Choi, {Kyung Mook}",
year = "2014",
month = "1",
day = "1",
doi = "10.1210/jc.2014-1195",
language = "English",
volume = "99",
pages = "2778--2785",
journal = "Journal of Clinical Endocrinology and Metabolism",
issn = "0021-972X",
publisher = "The Endocrine Society",
number = "8",

}

TY - JOUR

T1 - Implication of circulating irisin levels with brown adipose tissue and sarcopenia in humans

AU - Choi, Hae Yoon

AU - Kim, Sungeun

AU - Park, Ji Woo

AU - Lee, Nam Seok

AU - Hwang, Soon Young

AU - Huh, Joo Young

AU - Hong, Ho Cheol

AU - Yoo, Hye-Jin

AU - Baik, Sei-Hyun

AU - Youn, Byung Soo

AU - Mantzoros, Christos S.

AU - Choi, Kyung Mook

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.

AB - Context: Irisin is an exercise-induced novel myokine that drives brown-fat-like conversion of white adipose tissue and has been suggested to be a promising target for the treatment of obesity-related metabolic disorders. Objective: To assess the association of circulating irisin concentrations with brown adipose tissue (BAT) and/or sarcopenia in humans. SettingandDesign: Weexaminedirisin levels in40BAT-positiveand40BAT-negativewomendetected by 18F-fluorodeoxyglucose positron emission tomography (18FDG-PET). In a separate study, we also examined 401 subjects with or without sarcopenia defined by skeletal muscle mass index (SMMI) and appendicular skeletal muscle (ASM)/height2 using dual-energy x-ray absorptiometry. Results:Among6877 consecutive 18FDG-PET scans in 4736 subjects, 146 subjects (3.1%) had positive BAT scans. The BAT-detectable group and the matched BAT-undetectable group did not differ in circulating irisin levels measured using two different ELISA kits (P=.747 and P=.160, respectively). Serum irisin levels were not different between individuals with sarcopenia and those without sarcopenia using either kit (P = .305 and P = .569, respectively). Also, serum irisin levels were not different between groups defined by ASM/height2 using either kit (P = .352 and P = .134, respectively). Although visceral fat area and skeletal muscle mass showed significant difference according to tertiles of SMMI levels, irisin concentrations did not differ. Conclusions: Circulating irisin levels were not different in individuals with detectable BAT or those with sarcopenia compared with control subjects and were not correlated with SMMI.

UR - http://www.scopus.com/inward/record.url?scp=84905836995&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84905836995&partnerID=8YFLogxK

U2 - 10.1210/jc.2014-1195

DO - 10.1210/jc.2014-1195

M3 - Article

VL - 99

SP - 2778

EP - 2785

JO - Journal of Clinical Endocrinology and Metabolism

JF - Journal of Clinical Endocrinology and Metabolism

SN - 0021-972X

IS - 8

ER -